Kyowa Hakko Kirin Co., Ltd. established in October 2008, is a new pharmaceutical company built on a robust foundation of biotechnologies. Integrating the advanced therapeutic antibody technologies and R&D skills that the Kyowa Hakko Group and the Kirin Group have developed over the years, Kyowa Hakko Kirin is focused on creating new medical value in the strategic sectors of cancer, kidney, and immunity/infectious diseases. In order to contribute to the health and prosperity of people around the world as a Japan-based global pharmaceutical specialist, the company intends to take full advantage of its unique, cutting-edge technologies to create and distribute groundbreaking new drugs using a global development and marketing network.

Therapeutic antibodies, a particular specialty of Kyowa Hakko Kirin Co., Ltd. make use of a person’s immune abilities (defense systems against bacterial pathogens, etc.) to form the basis for the development of new pharmaceutical products. Accordingly, the company has already established a number of independent antibody technologies and is utilizing them to develop innovative new drugs. In small molecule pharmaceuticals, Kyowa Hakko Kirin is working to speed up development through the fusion of acquired technologies.